Fighting in Court Over MS Generics

Fighting in Court Over MS Generics

MS_Wire_Ed_Tobias
Biogen is a big pharmaceutical company that produces a half-dozen MS drugs. Among them are Tysabri, Avonex and Tecfidera. And Biogen is doing all it can to protect its turf, particularly when it comes to its best seller, Tecfidera.

Last month the company filed lawsuits against several pharmaceutical companies that are trying to develop generic versions of Tecfidera. According to an article in the Boston Business Journal, in the five days between June 26-30 Biogen filed 26 patent-infringement lawsuits in federal court against several competitors, including Mylan Pharmaceuticals and Sandoz.

The patents involved in the lawsuits expire over the next 10 years. In its suit against Sandoz, Biogen claims  it “will suffer substantial and irreparable harm for which there is no adequate remedy at law” if the court allows a generic version of Tecfidera to be marketed right now.

Tecfidera accounted for close to $4 billion in sales for Biogen last year. That’s more than a third of the company’s total drug sales. I wrote about the cost of Tecfidera back in January, noting that Biogen was hiking its price, and that of two other drugs, by about 8 percent. That increase followed other hikes in preceding months.

Other drug companies waging MS patent fights

Last March, a court invalidated three patents that had been protecting the MS drug Ampyra (dalfampridine), which is made by Acorda Therapeutics. At least two companies have indicated they’re interested in making a generic version of that drug. Though it helped my walking, I had to stop using Ampyra a few years ago because its out-of-pocket cost was too much for my budget.

Generics could ease the MS cost burden

The high cost of MS drugs is only one of the cost burdens that rest on the shoulders of MS patients. Earlier this year I wrote about a study by the Institute for Clinical and Economic Review that acknowledged this problem:

“A diagnosis of MS poses many burdens, including economic hardships that are underappreciated (sic) in most economic analyses of MS. These include lost wages from missed work, the need to transition from full- to part-time work, the inability to continue working, and the high cost of medications and medical equipment.”

Would the availability of generic drugs to treat multiple sclerosis help to relieve some of this burden? One would think so. I know that when a generic of Ampyra appears it will return to my medicine cabinet.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.
×
Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.
Average Rating
0 out of 5 stars. 0 votes.
My Rating:

6 comments

  1. Alan says:

    People often talk about the “high cost” of MS drugs, but don’t actually pay the high cost. Generics will still likely cost thousands – which will mean the insurance companies save money. Ultimately, it drives down costs, but not in a way that most patients will see any difference.

  2. MS Caregiver says:

    I find that after 30+ years of observing not only my husband with late stage MS and others – the drugs are nebulous for number of exacerbations, after all how can you tell how many you “would” have had without them. When my husband was diagnosed there were no drugs – only standard ones to treat unreliable symptoms. Men especially still progress to full disabled status regardless of drugs – invalid in the end usually with severe cognitive decline. The only drug that has helped is an alzheimer’s drug Galantamine which usually helps alzheimer’s patients for about 3 years. My husband has been on this for 10 and declines when removed. This drug “ups” the signal reception in the brain. This disease is too critical to continue to let PhRma lead patients down their money vulture path of “treatment” rather than a definitive cure.

    • Ed Tobias says:

      Hello MS Caregiver,

      I totally understand how you feel about whether MS drugs are actually effective. Since being diagnosed in 1980 I’ve declined but, fortunately, only slowly. And my decline has been physical, not mental. Like your husband, there were no DMDs when I was diagnosed, but I hoped on one of the first to come along: Avonex. Since then I’ve been on several others and I continue, now, on Lemtrada.

      I can’t agree with your comment that “Men especially still progress to full disabled status regardless of drugs…” I’m about to celebrate my 69th birthday and, based upon the path I’ve traveled since being diagnosed when I was 32, I expect to still be able to walk, slowly with my canes, and without MS-related cognitive decline into my final years.

      Have my drugs slowed the progress of my MS? I don’t know and I really don’t care. But, at this stage of my life with MS I’m not going to risk the chance that they’re the reason that I’m doing as well as I am.

      Ed

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This